Innoviva logo
Innoviva
INVA | NASDAQ
Chart Builder DCF Calculator
$18.49
-$0.54 (-2.84%)
At close: Nov 16, 2026, 4:00 PM ET
$18.49
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Innoviva Company Profile

Company profile explained

Company Profile

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

Key Executives

Name Position
Pavel Raifeld Chief Executive Officer & Director
Stephen Basso Chief Financial Officer
David Altarac Chief Medical Officer of IST
Marianne Zhen Chief Accounting Officer & Secretary
Patricia Drake Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc.

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 24, 2026 4 Filing
Aug 24, 2026 4 Filing
Aug 24, 2026 4 Filing
Aug 05, 2026 10-Q Quarterly Report
Aug 05, 2026 8-K Current Report
Jul 31, 2026 SC 13G Statement of acquisition of beneficial ownership b...
May 22, 2026 4 Filing
May 22, 2026 4 Filing
May 22, 2026 4 Filing
View All SEC Filings ➞
Innoviva
Innoviva logo
Country United States
IPO Date Oct 5, 2004
Industry Biotechnology
Sector Healthcare
Employees 159
CEO Pavel Raifeld

Contact Details

1350 Old Bayshore Highway Burlingame, California 94010 United States

Stock Details

Ticker Symbol INVA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001080014
CUSIP Number 45781M101
ISIN Number US45781M1018
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.